BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 12588808)

  • 1. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance.
    Dohán O; De la Vieja A; Paroder V; Riedel C; Artani M; Reed M; Ginter CS; Carrasco N
    Endocr Rev; 2003 Feb; 24(1):48-77. PubMed ID: 12588808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology.
    De La Vieja A; Dohan O; Levy O; Carrasco N
    Physiol Rev; 2000 Jul; 80(3):1083-105. PubMed ID: 10893432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
    Dohán O; Carrasco N
    Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A perspective view of sodium iodide symporter research and its clinical implications.
    Riesco-Eizaguirre G; Santisteban P
    Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
    Dohán O; De la Vieja A; Carrasco N
    Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
    Kogai T; Taki K; Brent GA
    Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and clinical application of the NIS gene.
    Elisei R; Vivaldi A; Pacini F
    Tumori; 2003; 89(5):523-8. PubMed ID: 14870777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
    Spitzweg C
    Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The practical relevance of the sodium iodide symporter].
    Spitzweg C
    Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa.
    Spitzweg C; Joba W; Eisenmenger W; Heufelder AE
    J Clin Endocrinol Metab; 1998 May; 83(5):1746-51. PubMed ID: 9589686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.
    Ravera S; Reyna-Neyra A; Ferrandino G; Amzel LM; Carrasco N
    Annu Rev Physiol; 2017 Feb; 79():261-289. PubMed ID: 28192058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
    Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
    Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells.
    Dentice M; Luongo C; Elefante A; Romino R; Ambrosio R; Vitale M; Rossi G; Fenzi G; Salvatore D
    Mol Cell Biol; 2004 Sep; 24(18):7863-77. PubMed ID: 15340050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
    Schmutzler C; Köhrle J
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number.
    De La Vieja A; Ginter CS; Carrasco N
    J Cell Sci; 2004 Feb; 117(Pt 5):677-87. PubMed ID: 14734652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sodium iodide symporter: its pathophysiological and therapeutic implications.
    Spitzweg C; Morris JC
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I- symporter.
    De la Vieja A; Ginter CS; Carrasco N
    Mol Endocrinol; 2005 Nov; 19(11):2847-58. PubMed ID: 15976004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
    Kogai T; Brent GA
    Pharmacol Ther; 2012 Sep; 135(3):355-70. PubMed ID: 22750642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands.
    Cho JY; Léveillé R; Kao R; Rousset B; Parlow AF; Burak WE; Mazzaferri EL; Jhiang SM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2936-43. PubMed ID: 10946907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Sodium/Iodide Symporter Compound Heterozygous Pathogenic Variants Causing Dyshormonogenic Congenital Hypothyroidism.
    Martín M; Bernal Barquero CE; Geysels RC; Papendieck P; Peyret V; Masini-Repiso AM; Chiesa AE; Nicola JP
    Thyroid; 2019 Jul; 29(7):1023-1026. PubMed ID: 31115276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.